A randomized, placebo-controlled trial to evaluate the tolerability, safety, pharmacokinetics, and pharmacodynamics of a potent inhibitor of poly(ADP-ribose) polymerase (INO-1001) in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: Results of the TIMI 37 trial
David A. Morrow*, Chaim M. Brickman, Sabina A. Murphy, Kenneth Baran, Ricardo Krakover, Harold Dauerman, Sujatha Kumar, Natanya Slomowitz, Laura Grip, Carolyn H. McCabe, Andrew L. Salzman
Research output: Contribution to journal › Article › peer-review
81Scopus
citations
Fingerprint
Dive into the research topics of 'A randomized, placebo-controlled trial to evaluate the tolerability, safety, pharmacokinetics, and pharmacodynamics of a potent inhibitor of poly(ADP-ribose) polymerase (INO-1001) in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: Results of the TIMI 37 trial'. Together they form a unique fingerprint.